Inflammatory complications of immunodeficiency disease may benefit from imaging technique

November 30, 2016
FDG PET-CT scan shows pre and three months' post treatment with immunosuppressant therapy in a patient with GLILD. Pre-treatment image shows widespread abnormal uptake of the tracer in the lung parenchyma and lymph nodes both above and below the diaphragm. After treatment, this is no longer the case. Credit: (C) S Jolles, University Hospital of Wales

A new proof of concept study has shown that an imaging technique more commonly used to assess cancer patients may also be of help in assessing disease and treatment effects in patients with inflammatory diseases. The study is published in Clinical & Experimental Immunology.

Common variable immunodeficiency (CVID) is the commonest serious primary immunodeficiency of adults. Patients are not only unable to manufacture antibodies to protect them from infections but also suffer from inflammatory and autoimmune complications. CVID affects approximately 1 in 25,000 adults. While treatment with antibody replacement and antibiotics has significantly improved infections, the non-infectious inflammatory, autoimmune and malignant complications have emerged as major therapeutic challenges. One complication of CVID is called granulomatous lymphocytic (GLILD). This is a complex condition to diagnose and monitor as onset may be insidious leading to lung involvement, enlarged lymph-nodes and spleen. Currently, a combination of clinical features, laboratory markers, lung function measures and radiological investigations are used to diagnose and make treatment decisions about GLILD though there remains a lack of information to help clinicians determine the optimal frequency of testing and timing of treatment.

In this proof of concept study, Dr Stephen Jolles and colleagues from the University Hospital of Wales used an imaging technique called FDG PET-CT to simultaneously assess and metabolic activity in a patient with GLILD. FDG PET-CT imaging allows the detailed anatomical structure obtained by a CT scan to be overlaid and combined with PET images of rates of labelled glucose uptake into cells within the tissues; the clinical utility of which has already been proven in oncological imaging. However, FDG PET-CT's use to assess inflammatory is an emerging field and this paper is the first time that this technique has been employed to assess both anatomical and metabolic extent of the disease and to assess treatment response in the setting of GLILD.

The images (supplied) show that FDG PET-CT provides new insights into GLILD, showing widespread, high levels of metabolic activity not restricted to the lungs but affecting lymph nodes (even when these are normal in size) throughout the body before treatment. After treatment, clear improvements in both anatomical and functional activity can be observed. The combined FDG PET-CT demonstrates that GLILD is only the pulmonary facet of a highly metabolically active multisystem disease. The very high levels of metabolic activity may have implications for the development of autoimmunity and malignancy, both of which occur at higher frequency in patients with GLILD.

PET-CT images of the upper chest pre and three months' post treatment with immunosuppressant therapy in a patient with GLILD are shown. The level of FDG uptake is shown by the intensity of color. Prior to treatment, an enlarged lymph node exhibits intense abnormal FDG uptake. Following treatment, the lymph node at this site normalizes in size and shows no abnormal tracer uptake. Credit: (c) S.Jolles, University Hospital of Wales

Larger studies are now needed to assess the potential role of this technology in the ongoing care of patients with GLILD and it is likely that it will be increasingly used in a wider range of inflammatory disorders.

Lead researcher Dr Stephen Jolles from the University Hospital of Wales said:

"Patients who develop granulomatous lymphocytic interstitial lung disease (GLILD) as a complication of common variable immunodeficiency (CVID) often have poorer outcomes. Given the multi-systemic nature of this disease, it is currently difficult for clinicians to accurately monitor and assess the optimal timing of treatment as well as the effect of treatment and its duration.

This study is the first time that the , FDG PET-CT, has been used to assess the combined lung structure and in a patient with GLILD before and after . The images are striking and enlightening in that they reveal the highly metabolically active multi-systemic nature of the disease. It remains to me amazing the ability of this technique to overlay structure with metabolic functional activity in this way."

Explore further: Immunodeficient patients with secondary lung disease benefit from combined chemotherapy

More information: S. Jolles et al, FDG PET-CT imaging of therapeutic response in granulomatous lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID), Clinical & Experimental Immunology (2016). DOI: 10.1111/cei.12856

Related Stories

Immunodeficient patients with secondary lung disease benefit from combined chemotherapy

August 30, 2012
A team of researchers at the Medical College of Wisconsin and Children's Hospital of Wisconsin Research Institute defined a new treatment for a potentially fatal lung disease in patients with a primary immunodeficiency known ...

Novel gene variants found in a difficult childhood immune disorder

February 26, 2015
Genomics researchers analyzing a rare, serious immunodeficiency disease in children have discovered links to a gene crucial to the body's defense against infections. The finding may represent an inviting target for drugs ...

IV immunoglobulin use up in interstitial lung disease

August 11, 2016
(HealthDay)—Intravenous immunoglobulin (IVIg) is increasingly being used for interstitial lung disease (ILD), despite a lack of evidence for its use, according to research published online Aug. 2 in the Annals of the American ...

Scientists identify epigenetic basis of common variable immunodeficiency through study of monozygotic twins

June 17, 2015
Researchers of the Chromatin and Disease Group from the Bellvitge Biomedical Research Institute (IDIBELL) and La Paz Hospital (IDIPAZ) have identified epigenetic alterations in Common Variable Immunodeficiency (CVID), the ...

Missing genetic link found in a challenging immune disease

April 22, 2015
In the largest genetic study to date of a challenging immunodeficiency disorder, scientists have identified a gene that may be a "missing link" between overactive and underactive immune activity. The gene candidate also plays ...

Development of autoimmunity in patients with common variable immune deficiency

September 24, 2013
Common variable immune deficiency (CVID) is a genetic disease associated with enhanced susceptibility to infection, autoimmunity, and decreased antibody production. Mutations in the tumor necrosis factor receptor superfamily ...

Recommended for you

Targeting 'broken' metabolism in immune cells reduces inflammatory disease

July 12, 2017
The team, led by researchers at Imperial College London, Queen Mary University of London and Ergon Pharmaceuticals, believes the approach could offer new hope in the treatment of inflammatory conditions like arthritis, autoimmune ...

A perturbed skin microbiome can be 'contagious' and promote inflammation, study finds

June 29, 2017
Even in healthy individuals, the skin plays host to a menagerie of bacteria, fungi and viruses. Growing scientific evidence suggests that this lively community, collectively known as the skin microbiome, serves an important ...

Inflammatory bowel disease: Scientists zoom in on genetic culprits

June 28, 2017
Scientists have closed in on specific genes responsible for Inflammatory Bowel Disease (IBD) from a list of over 600 genes that were suspects for the disease. The team from the Wellcome Trust Sanger Institute and their collaborators ...

Trials show unique stem cells a potential asthma treatment

June 28, 2017
A study led by scientists at Monash University has shown that a new therapy developed through stem cell technology holds promise as a treatment for chronic asthma.

Researchers find piece in inflammatory disease puzzle

May 23, 2017
Inflammation is the process by which the body responds to injury or infection but when this process becomes out of control it can cause disease. Monash Biomedicine Discovery Institute (BDI) researchers, in collaboration with ...

Researchers reveal potential target for the treatment of skin inflammation in eczema and psoriasis

May 22, 2017
Superficially, psoriasis and atopic dermatitis may appear similar but their commonalities are only skin deep. Atopic dermatitis, also known as eczema, is primarily driven by an allergic reaction, while psoriasis is considered ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.